Baird Cuts Price Target on Regeneron (REGN) as Late Stage Trials Hit Operating Costs - Reiterates Outperform

Go back to Baird Cuts Price Target on Regeneron (REGN) as Late Stage Trials Hit Operating Costs - Reiterates Outperform
Regeneron (NASDAQ: REGN) Delayed: 827.72 -15.75 (1.87%)
Previous Close $843.47    52 Week High $592.36 
Open $840.05    52 Week Low $325.35 
Day High $841.54    P/E 217.25 
Day Low $825.83    EPS $3.81 
Volume 561,170